Kristina Lövgren (Former)
1 – 10 of 39
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
(
- Contribution to journal › Article
-
Mark
The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
(
- Contribution to journal › Article
- 2019
-
Mark
The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
(
- Contribution to journal › Article
- 2018
-
Mark
Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases
(
- Contribution to journal › Article
- 2017
-
Mark
Myoepithelium assessment with p63 immunostaining in formalinfixed paraffin-embedded breast cancer tissue pre-treated with RNA-later
(
- Contribution to journal › Published meeting abstract
-
Mark
AIB1 is a new putative prognostic biomarker in the luminal A and B-like (HER2-negative) classification of invasive lobular carcinoma
(
- Contribution to conference › Abstract
- 2016
-
Mark
Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
(
- Contribution to journal › Article
- 2015
-
Mark
A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
(
- Contribution to journal › Article
-
Mark
Reply from Authors re: Bas W.G. van Rhijn, Mark A. Behrendt, Kees Hendricksen, Theo H. van der Kwast. Toward Optimal Prediction of Prognosis in T1 Urothelial Carcinoma of the Bladder. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.03.030.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.
(
- Contribution to journal › Article